{
    "nct_id": "NCT02816164",
    "official_title": "A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2)",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Histologically confirmed primary breast cancer\n* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\n* ≥19 years of age\n* Able to provide verbal consent\n\nExclusion Criteria:\n\n* Contraindication to Filgrastim\n\nsex: ALL\n\nminimumAge: 19 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Histologically confirmed primary breast cancer\n* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\n* ≥19 years of age\n* Able to provide verbal consent",
        "exclusion": "* Contraindication to Filgrastim"
    }
}